4KHAN ZP,FERGUSON CN, JONES RM. a|pha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role [ J ]. Anaesthesia, 1999,54 (2) : 146 - 165.
5HOFER RE, SPRUNG J, SARR MG, et al. Anesthesia for a patient with morbid obesity using dexmedetomidine without narcotics [ J ]. Can J Anaesth ,2005,52 ( 2 ) : 176 - 180.
6Afonsoa J, Reis F. Dexmedetomidine : current role in anesthesia and intensive care [ J ]. Rev Bras Artestesiol,2012,62 : 118 - 133.
7Kohli U, Pandharipande EP, Muszkat M, et al. CYP2A6 genetic var- iation and dexmedetomidine disposition[ J]. Eur J Clin Pharmacol, 2012,68:937 - 942.
8Fairbanks CA, Stone LS, Wilcox GL. Pharmacological profiles of al- pha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis[ J]. Pharmacol Ther,2009,123 : 224 - 238.
9Seyrek M, Halici Z,Yildiz O,et al. Interaction between dexmedeto- midine and alpha - adrenergic receptors: emphasis on vascular ac- tions[ J ] . J Cardiothorac Vasc Anesth,2011,25 :856 - 862.
10Iirola T, Vilo S, Manner T, et al. Bioavailability of dexmedetomidine after intranasal administration[ J]. Eur J Clin Pharmaco1,2011,67 : 825 - 831.
